Walgreens and Prothena announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety...
Astrocyte Pharmaceuticals Inc, a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation...
With the accelerated approval on January 6, 2023 for early Alzheimer's disease, Eisai/Biogen's Leqembi became only the second approved disease-modifying therapy (DMT) for early Alzheimer's...
C2N Diagnostics, a leader in advanced brain health diagnostics, announced the presentation of two research studies at the AD/PD 2023 International Conference on Alzheimer’s...
Cognito Therapeutics, announced neuroimaging results evaluating the effects of the company’s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in...
